Tri-Coast Pharmacy Recalls Taurine Vials Due to Sterility Concerns
Tri-Coast Pharmacy is recalling 90 vials of compounded Taurine 50 mg/mL because the products lack assurance of sterility.
The agency’s classification
FDA (Drugs): Class II
Class II is a situation in which use of or exposure to a violative product may cause temporary or medically reversible adverse health consequences, or where the probability of serious adverse health consequences is remote.
This is the agency’s own classification, taken from its notice. The severity score below is our assessment, not the agency’s. How recall classes work
What this means for you
Our assessment, not the agency’s: severity 4/5 (Severe).
The hazard poses a serious risk of illness, injury, or structural failure. Stop using the product immediately and contact the manufacturer for a refund or repair.
Our severity reasoning: The recall is classified as FDA Class II and involves a lack of assurance of sterility in a compounded pharmaceutical product, which poses a significant risk of infection or serious injury.
Plain-English summary
Tri-Coast Pharmacy is voluntarily recalling 90 vials of Taurine 50 mg/mL (30 mL) compounded by the firm. The recall is being conducted because the products lack assurance of sterility.
The recall includes all sterile products compounded between May 17, 2016, and November 17, 2016. Known lot codes with expiration dates are 06282016C (12/25/2016), 10242016A (10/27/2016), and 10212016A (10/24/2016). The products were distributed nationwide.
Consumers and healthcare providers should stop using the recalled products and contact their pharmacist or Tri-Coast Pharmacy for further instructions.
The recalled product
- Product
- Taurine 50 mg/mL, (30 ML). Compounded by Tri-Coast Pharmacy
- Manufacturer
- Tri-Coast Pharmacy
- Affected units
- 90
Is your product affected?
Check your packaging against the codes below. If any of them match, the product is part of this recall.
Lot numbers (2)
- 10242016A (10/27/2016)
- 10212016A (10/24/2016).
Distribution
Distributed nationwide across the United States.
Part of a larger recall action
This product is one of 80 recalled by Tri-Coast Pharmacy under a single FDA (Drugs) recall action. The agency files each product separately, so the size of the action is not visible from this page alone.
See all 80 products in this recall →Related recalls
Same manufacturer · Tri-Coast Pharmacy
See all →- SevereTri-Coast Pharmacy Recalls TriMix Injection Due to Sterility Concerns
FDA (Drugs) · 2017-01-11
- SevereTri-Coast Pharmacy Recalls Sermorelin Forte Due to Sterility Concerns
FDA (Drugs) · 2017-01-11
- SevereTri-Coast Pharmacy Recalls TriMix Injection Due to Sterility Concerns
FDA (Drugs) · 2017-01-11
- SevereTri-Coast Pharmacy Recalls BiMix Phentolamine/Papaverine Due to Sterility Concerns
FDA (Drugs) · 2017-01-11
- SevereTri-Coast Pharmacy Recalls Quad Mix Sterile Compounded Drug
FDA (Drugs) · 2017-01-11
Same hazard · lack of sterility
See all →- SevereK.C. Pharmaceuticals Recalls Dry Eye Relief Eye Drops for Sterility Concerns
FDA (Drugs) · 2026-10-14
- SevereK.C. Pharmaceuticals Recalls Multiple Brands of Eye Drops for Sterility Concerns
FDA (Drugs) · 2026-10-14
- SevereClear Eyes Redness Relief Eye Drops Recalled for Sterility Concerns
FDA (Drugs) · 2026-09-30
- SevereClear Eyes Redness Relief Eye Drops Recalled for Sterility Assurance Issues
FDA (Drugs) · 2026-09-30
- SevereGentle Eyes Lubricant Eye Drops Recalled for Sterility Concerns
FDA (Drugs) · 2026-09-30
Similar recalls
- SevereMedaus Recalls Taurine Vials Due to Lack of Sterility Assurance
FDA (Drugs) · 2016-07-20
- HighDowning Labs Recalls Taurine Injectable Due to Sterility Concerns
FDA (Drugs) · 2015-11-25
- SevereGreen Valley Drugs Recalls Taurine Injection Due to Sterility Concerns
FDA (Drugs) · 2013-05-22
- SevereMedaus Recalls Taurine 50 mg/mL PF Due to Sterility Concerns
FDA (Drugs) · 2013-09-25
- SevereRXQ Compounding Recalls Taurine Injectable Due to Sterility Concerns
FDA (Drugs) · 2019-08-14
- SevereWalgreens Recalls Thiamine Vials Due to Sterility Assurance Concerns
FDA (Drugs) · 2015-01-28